Clinical and Translational Allergy
The influence of nutritional habits, body mass index and intestinal microbiota in mastocytosis on clinical symptoms using conventional culture and next generation sequencing.
Harcęko-Zielińska E, Niedoszytko M, Górska A, et al.
This study demonstrates that patients with mastocytosis have similar nutritional habits and BMI compared with the general population. The low richness of microbiota species may contribute to gastrointestinal symptoms experienced by patients with mastocytosis. Option 2: Learn about dietary habits, BMI, and microbiota diversity in patients with indolent systemic mastocytosis.
Previous Article
- • Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: a nationwide multicenter retrospective analysis.
- • Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy
- • Plasma protein profiling to discern indolent from advanced systemic mastocytosis
- • Indolent systemic mastocytosis (ISM) without skin lesions as a recurrent anaphylaxis: a case report study.
- • Safety of a mRNA COVID-19 vaccine in patients with indolent systemic mastocytosis.
- • Avapritinib versus placebo in indolent systemic mastocytosis.
- • The influence of nutritional habits, body mass index and intestinal microbiota in mastocytosis on clinical symptoms using conventional culture and next generation sequencing.
- • Genome-wide DNA methylation and gene expression in patients with indolent systemic mastocytosis.
- • Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.
- • Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches.
- • Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms.
- • The international consensus classification of mastocytosis and related entities.
- • Developments in Clinical and Translational IgAN Research
- • The CURE-CKD Registry
- • Non-Invasive Diagnostic Tools in IgA Nephropathy
- • Efficacy and Safety of Endothelin A Receptor Antagonists in IgA Nephropathy
- • Hydroxychloroquine Regulates Intestinal Flora and Glycosyltransferase Activity in Rats With IgA Nephropathy
- • Genetic Implications for IgA Nephropathy Therapy
- • Global Epidemiology of IgA Nephropathy
- • The Mastocytosis Control Test for Assessing Disease Control
- • Delphi Consensus for Managing Adverse Events in Patients With Metastatic Triple-Negative Breast Cancer Receiving Sacituzumab Govitecan
- • The Safety and Effectiveness of Palbociclib in Clinical Practice
- • Determinants of HER2-Targeted Therapy Use in Metastatic HR-/HER2+ Breast Cancer
- • Equity of Care Across Metastatic Breast Cancer Treatment
- • Tumor Growth Rate and Survival in Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- • Patient-Reported Outcomes From DESTINY-Breast04
- • Prognostic Significance of TILs in HER2+ Metastatic Breast Cancer
- • Real-World Consensus on Treating HR+/HER2- Metastatic Breast Cancer
- • Animal Models in Metastatic Breast Cancer Immunotherapy Research
- • PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders
- • Smartphone-Based Monitoring of Chronic Kidney Disease
- • The Validated Mastocytosis Control Test for Measuring Disease Control
